Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

  • Technology appraisal
  • TA351
  • Published: 

Tools and resources

Guidance into practice